Michael Emig

Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma

Yago Nieto, Pinaki P. Banerjee, Indreshpal Kaur et al. · Blood · 2022 · 23 citations

Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results

Yago Nieto, Pinaki P. Banerjee, Indreshpal Kaur et al. · Blood · 2023 · 19 citations

Abstract CT024: REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL)

Won Seog Kim, Jake Shortt, Pier Luigi Zinzani et al. · Cancer Research · 2023 · 14 citations

Immunodeficiencies, Immunology, Immune Regulation +22

AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgkin Lymphoma and CD30 + Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE)

Alison J. Moskowitz, A. Harstrick, Michael Emig et al. · Blood · 2023 · 11 citations

Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort.

Anthony B. El-Khoueiry, Delcia Rivas, Se‐Hoon Lee et al. · Journal of Clinical Oncology · 2023 · 10 citations